Abstract: The present invention provides a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, for example for use in a malaria vaccine. The present invention also provides nucleic acids encoding a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1, compositions comprising a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1 and antibodies binding to a fragment of plasmodium circumsporozoite protein according to SEQ ID NO: 1. The antibodies according to the present invention bind specifically to P. falciparum sporozoites and may be used in the treatment and/or prevention of malaria.

Abstract: A product such as a food product, food ingredient, food supplement or medicament containing isolated Prevotella copri (P. copri). The food product, food ingredient and food supplement are suitable for ingestion and the medicament is suitable for use as a suppository or enema or enclosed in a capsule.

Abstract: The present application is generally directed to methods for identifying immunogens from organisms and pathogens, and in particular for identifying immunogens which when administered as vaccines elicit a cellular and/or humoral immune response. The present application is also directed to pneumococcal T-cell immunogens, and vaccine compositions comprising one or a combination of pneumococcal immunogens and methods for treating or preventing pneumococcal infections using the vaccines thereof. The present invention also encompasses use of the pneumococcal immunogens for diagnostic purposes to identify a subject with a pneumococcal infection.

Abstract: Methods for generating immune responses using adenovirus vectors that allow multiple vaccinations with the same adenovirus vector and vaccinations in individuals with preexisting immunity to adenovirus are provided.

Abstract: The present disclosure provides isolated Pseudomonas koreensis strains useful for enhancing crop yield, as well as inoculant compositions comprising one or more of the isolated strains, seeds that have been treated with one or more of the isolated strains, and methods of using the isolated strains to enhance root growth, nutrient uptake, chlorophyll content, etc.

Abstract: The present invention relates to methods for producing compositions comprising secretory IgA and one or more probiotics. In particular, the invention relates to methods for producing compositions in which the secretory IgA and one or more probiotics are associated. The invention also relates to compositions obtainable by the methods and uses of the compositions, for example in reducing or preventing a non-viral infection and/or inflammation.

Abstract: Single-domain antibodies (SAbs) against three Yersinia pestis surface proteins (LcrV, YscF, and F1), nucleic acid sequences encoding the SAbs, and polypeptides comprising two or more SAbs capable of recognizing two or more epitopes and/or antigens. The present invention further includes methods for preventing or treating Y. pestis infections in a patient; methods for detecting and/or diagnosing Y. pestis infections; and devices and methods for identifying and/or detecting Y. pestis on a surface and/or in an environment.

Abstract: Disclosed are a Penicillium oxalicum SDF-25 strain and applications thereof, which relate to the technical field of environmental microorganisms. The Penicillium oxalicum SDF-25 strain has a strain preservation number of CGMCC No. 19272. The Penicillium oxalicum SDF-25 strain can be applied to straw degradation. The Penicillium oxalicum SDF-25 strain provided in the present solution can grow normally at 6 to 37° C. The Penicillium oxalicum SDF-25 strain can secrete a large amount of carboxymethyl cellulase at 10 to 16° C., and still produce enzyme at 6° C. The highest enzymatic activity can reach 993.3 U/mL.

Abstract: The present invention relates to compositions and fusion proteins containing at least two Mycobacterium sp. antigens, and polynucleotides encoding such compositions and fusion proteins. The invention also relates to methods for their use in the treatment, prevention and/or diagnosis of tuberculosis infections.

Abstract: The present invention provides mutated fHbp polypeptides and fusion proteins comprising said mutated fHbp polypeptides that are useful as components of immunogenic compositions for immunizing against Neisseria meningitidis infection.

Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.

Abstract: A strain of selenium-enriched Lactiplantibacillus plantarum KD-2 and applications in fermented goat milk and goat milk powder are provided in the present disclosure. The strain is preserved in China Center for Type Culture Collection on Apr. 13, 2023, with a deposit number of CCTCC NO: M2023478. The Lactiplantibacillus plantarum KD-2 is capable of reducing sodium selenite under a condition of buffer solution to prepare nano-selenium, which does not need to be carried out in a culture medium. The Lactiplantibacillus plantarum KD-2 is used to prepare selenium-enriched probiotic fermented goat milk, selenium-enriched probiotics and nano-selenium, and the selenium-enriched probiotics and nano-selenium are applied to goat milk powder.

Abstract: In this application is described a mutant Acinobacter baumannii strain having a deletion or mutation in its genome. The deletion or mutation interrupts the proper translation of the Hcp protein.

Abstract: Embodiments of the disclosure are related to a method of treating cancer including preventative treatment comprising administering nitrous oxide and oxygen to the patient by inhalation, and/or administering a botulinum toxin to the patient by injection, wherein the latter is directed to preventative treatment.

Abstract: The disclosure discloses a strain of Lactobacillus rhamnosus and application thereof in inhibiting Helicobacter pylori, and belongs to the technical fields of microorganisms and medicine. The disclosure provides a strain of Lactobacillus rhamnosus CCFM1119. The Lactobacillus rhamnosus CCFM1119 can prevent and/or treat Helicobacter pylori infection, specifically embodied in that: (1) the Lactobacillus rhamnosus CCFM1119 can significantly relieve the gastrointestinal symptoms of patients with Helicobacter pylori infection; (2) the Lactobacillus rhamnosus CCFM1119 can significantly reduce the amount of colonization of Helicobacter pylori in patients with Helicobacter pylori infection; and (3) the Lactobacillus rhamnosus CCFM1119 can significantly increase the clearance rate of Helicobacter pylori in patients with Helicobacter pylori infection.

Abstract: Disclosed herein are immunogenic compositions for preventing or treating infection with filarial parasites and biomarkers for diagnosing infection with filarial parasites.

Abstract: Provided herein are agents that bind to the lipid binding groove of Frizzled (FZD). In some embodiments, the agent is a fragment of TcdB corresponding to amino acids 1285-1804 of SEQ ID NO: 1. In some embodiments, binding of the agent to the lipid binding groove of FZD inhibits TcdB entry into cells, and/or inhibits Wnt signaling. Methods of treating Clostridium difficile infection (CDI) and methods of treating cancer are also provided.

Abstract: Disclosed herein is the use a cyanobacterial biomass for treating hepatitis B virus (HBV) infection, in particular, chronic HBV infection. According to various embodiments of the present disclosure, the cyanobacterial biomass, upon administration of at least one month, significantly reduces the level of the surface antigen of hepatitis B virus (HBsAg) detectable in the subject receiving the treatment and/or mitigates insomnia associated with chronic HBV infection.

Abstract: The present invention relates to pharmaceutical vaccine compositions comprising at least one vaccine antigen together with living immune cells. These immune cells include at least a portion of activated T-cells and act as an adjuvant. Methods for using these pharmaceutical compositions to prevent or treat diseases, such as cancer, infectious diseases and autoimmune disease are also included.

Abstract: Methods of treating or inhibiting inflammation in a subject include administering an anti-inflammatory protein to the subject. In some embodiments, the protein has at least 80% sequence identity to the amino acid sequence set forth as SEQ ID NO: 1, SEQ ID NO: 11, or fragments thereof. Isolated polypeptides, nucleic acids, and recombinant vectors including a nucleic acid encoding the anti-inflammatory protein (such as a nucleic acid encoding a protein with at least 80% sequence identity to SEQ ID NO: 1, SEQ ID NO: 11, or fragments thereof) operably linked to a heterologous promoter are also disclosed.